Zepbound 2nd Appeal copy/paste (4 scenarios)
4 Scenarios
Zepbound + Obesity + No prior Wegovy/GLP-1s
**Urgent Second-Level Appeal and Request for Expedited External Review**
I am submitting this urgent and expedited external second-level appeal to request a formulary exception for Zepbound, which my healthcare provider has prescribed for the treatment of obesity.
My initial request was denied on the grounds that Zepbound is not considered medically necessary and that formulary alternatives—specifically Wegovy and Mounjaro—should be used instead. However, the denial relied on vague and misleading language suggesting Wegovy is an equivalent substitute, despite clinical evidence—such as the SURMOUNT-5 study—demonstrating Zepbound’s superior efficacy and tolerability. It also implied that Mounjaro, a tirzepatide-based drug not FDA-approved for chronic weight management, could be used instead, without disclosing that such off-label substitution carries legal, clinical, and coverage risks.
No clinical criteria or plan provisions were cited nor provided despite formal requests to support these conclusions.
To that end, I urge you to carefully review my enclosed first-level appeal letter and all supporting documentation submitted therein, which collectively outline the medical, legal, and personal circumstances that demand individualized consideration. These materials were prepared specifically to ensure a comprehensive and fair evaluation of my case and must be weighed in full before any decision is made. Forcing any patient such as myself to switch to a non-equivalent or off-label medication is medically inappropriate and legally questionable.
**I have included a legal opinion from independent healthcare attorney Brian P. Hufford (see Appendix), which identifies multiple violations of federal law in CVS Caremark’s handling of Zepbound claims. His review raises serious concerns, including:**
—The use of boilerplate denial language that fails to consider my individual medical history, in violation of ERISA’s “full and fair review” requirements.
—Formulary decisions that appear to be driven by rebate contracts rather than medical necessity—violating fiduciary duties to act solely in the interest of plan participants.
—A disregard for robust clinical evidence supporting Zepbound’s safety and effectiveness, including findings from the SURMOUNT-5 trial.
—Steering patients toward off-label use of Mounjaro, a drug not FDA-approved for obesity, exposing patients to clinical and coverage risks without disclosure given it may be denied, revoked, or excluded at any time—without notice or recourse.
—Omission of the reviewing physician’s identity and qualifications, as required by ERISA.
**For these reasons, I respectfully request immediate reconsideration and an expedited (72-hour) external second-level review under the Affordable Care Act (45 C.F.R. § 147.136), based on the following:**
—**Urgency**: This denial affects ongoing treatment for a serious condition. My case meets the federal definition of an “urgent care claim” (29 C.F.R. § 2560.503-1(m)(4)), and my provider has documented the medical necessity of Zepbound. Delays could harm my health.
— **No Equivalent Alternative**: I am stable on Zepbound, an FDA-approved therapy with no clinically equivalent substitute. Forcing a switch to a less effective or off-label option undermines my provider’s medical judgment and may violate ERISA and ACA protections.
— **Request for Records**: I have previously requested, but not received, the internal guidelines, protocols, and supporting documents relied upon in this denial. Please treat this as a second formal and binding request for all plan documents and claim file materials, as required under ERISA and ACA (see Appendix: Initial Appeal).
I ask you to overturn the prior plan level improper denial that ignored the provided extensive evidence, clinical facts and tests that demonstrate the medical necessity of Zebound for my care.
Zepbound + Obesity + Prior Wegovy Try + Fail
**Urgent Second-Level Appeal and Request for Expedited External Review**
I am submitting this urgent and expedited external second-level appeal to request a formulary exception for Zepbound, which my healthcare provider has prescribed for the treatment of obesity.
My initial request was denied on the grounds that Zepbound is not considered medically necessary and that formulary alternatives—specifically Wegovy and Mounjaro—should be used instead. However, the denial relied on vague and misleading language suggesting Wegovy is an equivalent substitute, despite clinical evidence—such as the SURMOUNT-5 study—demonstrating Zepbound’s superior efficacy and tolerability. It also implied that Mounjaro, a tirzepatide-based drug not FDA-approved for chronic weight management, could be used instead, without disclosing that such off-label substitution carries legal, clinical, and coverage risks.
No clinical criteria or plan provisions were cited nor provided despite formal requests to support these conclusions.
Critically: I have already met the plan requirements of the denial and have previously tried and failed Wegovy. I should not be forced to fail it again before being approved for the medically necessary care my provider has requested.
To that end, I urge you to carefully review my enclosed first-level appeal letter and all supporting documentation submitted therein, which collectively outline the medical, legal, and personal circumstances that demand individualized consideration. These materials were prepared specifically to ensure a comprehensive and fair evaluation of my case and must be weighed in full before any decision is made. Forcing any patient such as myself to switch to a non-equivalent or off-label medication is medically inappropriate and legally questionable.
**I have included a legal opinion from independent healthcare attorney Brian P. Hufford (see Appendix), which identifies multiple violations of federal law in CVS Caremark’s handling of Zepbound claims. His review raises serious concerns, including:**
—The use of boilerplate denial language that fails to consider my individual medical history, in violation of ERISA’s “full and fair review” requirements.
—Formulary decisions that appear to be driven by rebate contracts rather than medical necessity—violating fiduciary duties to act solely in the interest of plan participants.
—A disregard for robust clinical evidence supporting Zepbound’s safety and effectiveness, including findings from the SURMOUNT-5 trial.
—Steering patients toward off-label use of Mounjaro, a drug not FDA-approved for obesity, exposing patients to clinical and coverage risks without disclosure given it may be denied, revoked, or excluded at any time—without notice or recourse.
—Omission of the reviewing physician’s identity and qualifications, as required by ERISA.
**For these reasons, I respectfully request immediate reconsideration and an expedited (72-hour) external second-level review under the Affordable Care Act (45 C.F.R. § 147.136), based on the following:**
—**Urgency**: This denial affects ongoing treatment for a serious condition. My case meets the federal definition of an “urgent care claim” (29 C.F.R. § 2560.503-1(m)(4)), and my provider has documented the medical necessity of Zepbound. Delays could harm my health.
— **No Equivalent Alternative**: I am stable on Zepbound, an FDA-approved therapy with no clinically equivalent substitute. Forcing a switch to a less effective or off-label option undermines my provider’s medical judgment and may violate ERISA and ACA protections.
— **Request for Records**: I have previously requested, but not received, the internal guidelines, protocols, and supporting documents relied upon in this denial. Please treat this as a second formal and binding request for all plan documents and claim file materials, as required under ERISA and ACA (see Appendix: Initial Appeal).
I ask you to overturn the prior plan level improper denial that ignored the provided extensive evidence, clinical facts and tests that demonstrate the medical necessity of Zebound for my care.
Zepbound + OSA + No prior Wegovy/GLP-1s
**Urgent Second-Level Appeal and Request for Expedited External Review**
I am submitting this urgent and expedited external second-level appeal to request a formulary exception for Zepbound, which my healthcare provider has prescribed for the treatment of my obstructive sleep apnea and associated obesity.
My initial request was improperly denied on the grounds that Zepbound is not considered medically necessary and that formulary alternatives—specifically Wegovy and Mounjaro—should be used instead. None of the evidence I had provided in my appeal was considered, as I clearly qualify per plan terms.
The denial relied on vague and misleading language suggesting Wegovy is deeply flawed. It is not an equivalent substitute, the SURMOUNT-5 study conclusively demonstrated Zepbound’s superior efficacy and tolerability. It also implied that Mounjaro, a tirzepatide-based drug not FDA-approved for chronic weight management, could be used instead, without disclosing that such off-label substitution carries legal, clinical, and coverage risks. No clinical criteria or plan provisions were cited nor provided despite formal requests to support these conclusions.
Moreover: I have been diagnosed with Obstructive Sleep Apnea. Zepbound is approved by the FDA for the treatment of OSA, Wegovy is not. These medications are not equivalent for my care.
To that end, I urge you to carefully review my enclosed first-level appeal letter and all supporting documentation submitted therein, which collectively outline the medical, legal, and personal circumstances that demand individualized consideration. These materials were prepared specifically to ensure a comprehensive and fair evaluation of my case and must be weighed in full before any decision is made. These provided materials demonstrate my stability and clinical progress on Zepbound. Forcing any patient such as myself to switch to a non-equivalent or off-label medication is medically inappropriate and legally questionable.
**I have included a legal opinion from independent healthcare attorney Brian P. Hufford (see Appendix), which identifies multiple violations of federal law in CVS Caremark’s handling of Zepbound claims. His review raises serious concerns, including:**
—The use of boilerplate denial language that fails to consider my individual medical history, in violation of ERISA’s “full and fair review” requirements.
—Formulary decisions that appear to be driven by rebate contracts rather than medical necessity—violating fiduciary duties to act solely in the interest of plan participants.
—A disregard for robust clinical evidence supporting Zepbound’s safety and effectiveness, including findings from the SURMOUNT-5 trial.
—Steering patients toward off-label use of Mounjaro, a drug not FDA-approved for obesity, exposing patients to clinical and coverage risks without disclosure given it may be denied, revoked, or excluded at any time—without notice or recourse.
—Omission of the reviewing physician’s identity and qualifications, as required by ERISA.
**For these reasons, I respectfully request immediate reconsideration and an expedited (72-hour) external second-level review under the Affordable Care Act (45 C.F.R. § 147.136), based on the following:**
—**Urgency**: This denial affects ongoing treatment for a serious condition. My case meets the federal definition of an “urgent care claim” (29 C.F.R. § 2560.503-1(m)(4)), and my provider has documented the medical necessity of Zepbound. Delays could harm my health.
— **No Equivalent Alternative**: I am stable on Zepbound, an FDA-approved therapy with no clinically equivalent substitute. Forcing a switch to a less effective or off-label option undermines my provider’s medical judgment and may violate ERISA and ACA protections.
— **Request for Records**: I have previously requested, but not received, the internal guidelines, protocols, and supporting documents relied upon in this denial. Please treat this as a second formal and binding request for all plan documents and claim file materials, as required under ERISA and ACA (see Appendix: Initial Appeal).
I ask you to overturn the prior improper denial that ignored the provided extensive evidence, clinical facts and tests that demonstrate the medical necessity of Zebound for my obstructive sleep apnea care.
Zepbound + OSA + Prior Wegovy Try + Fail
**Urgent Second-Level Appeal and Request for Expedited External Review**
I am submitting this urgent and expedited external second-level appeal to request a formulary exception for Zepbound, which my healthcare provider has prescribed for the treatment of my obstructive sleep apnea and associated obesity.
My initial request was improperly denied on the grounds that Zepbound is not considered medically necessary and that formulary alternatives—specifically Wegovy and Mounjaro—should be used instead. None of the evidence I had provided in my appeal was considered, as I clearly qualify per plan terms.
The denial relied on vague and misleading language suggesting Wegovy is deeply flawed. It is not an equivalent substitute, the SURMOUNT-5 study conclusively demonstrated Zepbound’s superior efficacy and tolerability. It also implied that Mounjaro, a tirzepatide-based drug not FDA-approved for chronic weight management, could be used instead, without disclosing that such off-label substitution carries legal, clinical, and coverage risks. No clinical criteria or plan provisions were cited nor provided despite formal requests to support these conclusions.
Moreover: I have been diagnosed with Obstructive Sleep Apnea. Zepbound is approved by the FDA for the treatment of OSA, Wegovy is not. These medications are not equivalent for my care.
Crucially: I have met the plan's stipulated, though legally questionable criteria. I have previously tried and failed Wegovy. I therefore should be approved for an FDA-indicated Tirzepatide product such as Zepbound.
To that end, I urge you to carefully review my enclosed first-level appeal letter and all supporting documentation submitted therein, which collectively outline the medical, legal, and personal circumstances that demand individualized consideration. These materials were prepared specifically to ensure a comprehensive and fair evaluation of my case and must be weighed in full before any decision is made. Forcing any patient such as myself to switch to a non-equivalent or off-label medication is medically inappropriate and legally questionable.
**I have included a legal opinion from independent healthcare attorney Brian P. Hufford (see Appendix), which identifies multiple violations of federal law in CVS Caremark’s handling of Zepbound claims. His review raises serious concerns, including:**
—The use of boilerplate denial language that fails to consider my individual medical history, in violation of ERISA’s “full and fair review” requirements.
—Formulary decisions that appear to be driven by rebate contracts rather than medical necessity—violating fiduciary duties to act solely in the interest of plan participants.
—A disregard for robust clinical evidence supporting Zepbound’s safety and effectiveness, including findings from the SURMOUNT-5 trial.
—Steering patients toward off-label use of Mounjaro, a drug not FDA-approved for obesity, exposing patients to clinical and coverage risks without disclosure given it may be denied, revoked, or excluded at any time—without notice or recourse.
—Omission of the reviewing physician’s identity and qualifications, as required by ERISA.
**For these reasons, I respectfully request immediate reconsideration and an expedited (72-hour) external second-level review under the Affordable Care Act (45 C.F.R. § 147.136), based on the following:**
—**Urgency**: This denial affects ongoing treatment for a serious condition. My case meets the federal definition of an “urgent care claim” (29 C.F.R. § 2560.503-1(m)(4)), and my provider has documented the medical necessity of Zepbound. Delays could harm my health.
— **No Equivalent Alternative**: I am stable on Zepbound, an FDA-approved therapy with no clinically equivalent substitute. Forcing a switch to a less effective or off-label option undermines my provider’s medical judgment and may violate ERISA and ACA protections.
— **Request for Records**: I have previously requested, but not received, the internal guidelines, protocols, and supporting documents relied upon in this denial. Please treat this as a second formal and binding request for all plan documents and claim file materials, as required under ERISA and ACA (see Appendix: Initial Appeal).
I ask you to overturn the prior improper denial that ignored the provided extensive evidence, clinical facts and tests that demonstrate the medical necessity of Zebound for my obstructive sleep apnea care.